RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Arkitekt Ventures
A

Arkitekt Ventures portfolio

Arkitekt Ventures has 2 portfolio companies on record at Recent Funding.

Type: Venture capital.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 0.
Capital in their rounds: $17M.
Latest deal: Olli Health · Nov 3, 2025.
About this page

It is a venture capital firm based in New York, US, founded in 2013. Its most recent investment on record is Olli Health's $10M Series A round in November 2025, alongside Cannage Capital, Tau Ventures and Industry Ventures. By category, its portfolio leans toward Health and bio (2) and AI coding and devtools (1). It has co-invested with Tau Ventures, Industry Ventures and Cannage Capital.

About Arkitekt Ventures

Firm type: Venture capital.
Headquarters: New York, US.
Founded: 2013.
Stages: Seed, Series A.
Sectors: AI & Machine Learning, Biotech, Consumer, Deep Tech, Healthtech, Medical Devices.
Check size: $100K to $10M.
Leads rounds: No.

What Arkitekt Ventures invests in

How Arkitekt Ventures invests

StageDealsCapital in rounds
Series A 2 100%$17M

Arkitekt Ventures portfolio companies

CompanyRound with Arkitekt VenturesTotal raisedLatest raise
OOlli Health
AI coding and devtools
Series A · $10M$13MNov 3, 2025
Series A
CCofertility
Health and bio
Series A · $7M$12MApr 10, 2025
Series A

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 2 rounds on Recent Funding that name Arkitekt Ventures. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Arkitekt Ventures, which is a subset of its real portfolio. API: /api/v1/investors/arkitekt-ventures (get a free API key). More: the most active VC firms and new venture capital funds.